Cabergoline treatment in acromegaly: cons

Area of Science:

• Endocrinology
• Pharmacology

Background:

• Acromegaly treatment involves surgery, radiotherapy, and medical options.
• Cabergoline (CAB), a dopamine agonist, is used alone or with somatostatin analogs (SSAs).

Purpose of the Study:

• To evaluate the utility of Cabergoline (CAB) in acromegaly treatment.
• To address the limited evidence supporting CAB compared to other acromegaly therapies.

Main Methods:

• Literature review of studies on Cabergoline for acromegaly.
• Comparison of CAB with somatostatin analogs (SSAs) and pegvisomant.

Main Results:

• Cabergoline is an orally administered, lower-cost alternative to SSAs.
• Few studies and a lack of randomized controlled trials exist for CAB in acromegaly.
• SSAs and pegvisomant have more extensive supporting literature.

Conclusions:

• Limited evidence and trial data are significant drawbacks for adopting Cabergoline in acromegaly management.
• Further research, including randomized controlled trials, is needed to establish CAB's role.